Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Ginkgo Bioworks

Cathie Wood snaps up 130,000 shares of plummeting, $1 stock

Ark Invest is continuing to snag shares of a biotech firm’s declining stock.

The Street

Cathie Wood Dives Deeper Into Two Big Biotech Stocks

Ark Invest loves its tech stocks.

The Street

Why the CDC is inviting travelers from China to swab their noses at LAX

LAX's arrivals area in the Tom Bradley International Terminal is now filling with the sounds of Mandarin, Cantonese, Hunanese and other languages as travelers from China seize the chance to enter the United States for the first time in nearly three years.

Los Angeles Times

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks to Buy Before December and 1 to Sell

The biotech industry is increasingly gaining prominence due to the growing prevalence of chronic disease and advancements in drug discovery and development. Given the industry’s solid growth prospects, it could be wise to buy quality biotech stocks, Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and United Therapeutics (UTHR). However, we think…

StockNews.com

Ginkgo Bioworks Goes to Saudi Arabia, Risking ESG Claims

The synthetic biology pioneer and the Kingdom of Saudi Arabia are exploring a technology partnership.

The Street

Ginkgo Bioworks Goes Big by Staying Small

Ginkgo's recent focus on drug development programs will avoid certain manufacturing risks. It also may hurt the stock's valuation.

The Street

The Worst Biotech Stock to Own in September

Biotech stock Ginkgo Bioworks (DNA) has fallen more than 60% year-to-date. The company has been making some acquisitions recently to aid its growth over the next few years. However, given its weak financials and unfavorable analyst estimates, it may not be wise to invest in this stock now. Continue reading….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Ginkgo Bioworks is Toying With Wall Street

The synthetic biology pioneer has underpromised and over-delivered on biosecurity revenue in 2022. Here's what comes next.

The Street

Is Ginkgo Bioworks Putting Its $1.5 Billion Cash Hoard to Good Use?

The synthetic biology leader's healthy cash balance provides plenty of breathing room, but it won't last forever.

The Street

3 Biotech Stocks That May Take Awhile to Recoup

How many years of future revenue and earnings were investors paying for in 2021? In some cases, quite a few.

The Street

5 Biotechs with $1 Billion in Cash

Worried about a recession? These cashed-up biotech stocks aren't sweating it.

The Street

Cronos Partners With Geocann To Launch CBD Gel Capsules By Lord Jones Utilizing VESIsorb For Faster Absorption

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) launched the first of what is expected to be a range of products, in partnership with Geocann, which will utilize the VESIsorb delivery system.

Benzinga

Why Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos Group

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 7.63% to $2.68 after the company, and Cronos Group Inc (NASDAQ: CRON), announced the achievement of the third target productivity milestone in their par

Benzinga

Tesla Bull Cathie Wood Scoops Up $11.5M In Bill Gates-Backed Biotech's Stock

Ark Investment Management, led by Tesla Inc.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

BofA Downgrades Ginkgo Bioworks, Cuts Price Target In Half

While Ginkgo Bioworks Holdings Inc’s (NYSE: DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to BofA Securities.

Benzinga

Why Ginkgo Bioworks Stock Is Falling After Hours

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower in Monday's after-hours session after the company

StockNews.com

Is Ginkgo Bioworks a Buy Under $5?

Cell programming platform operator Ginkgo Bioworks (DNA) went public late last year in an SPAC merger. Since then, the stock has plummeted more than 60% in price, closing yesterday’s session at $4.13. In addition, analysts have increased their loss per share expectations for the stock for this year. So, would…

Benzinga

Here's Why Ginkgo Bioworks Shares Are Rising

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 22.0% at $4.56 after the company reported better-than-expected fourth-quarter sales results and issued FY22 sales guidance above analyst estimates.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Ginkgo Bioworks Shares Gain As Q4 Sales, FY22 Guidance Surpass Street Expectations

Ginkgo Bioworks Holdings Inc (NYSE: DNA) reported

Benzinga

Why Ginkgo Bioworks Stock Is Rising After Hours

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is trading higher in Monday's after-hours session after the company reported financial results and issued guidance above estimates.

Benzinga

Ginkgo Bioworks Adds Ultra-High-Throughput Screening Platform Via FGen Acquisition

Ginkgo Bioworks Holdings Inc (NYSE: DNA) has

Benzinga

Why BofA Sees 'Better Entry Point' In Ginkgo Bioworks Stock

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities.

Benzinga

Ginkgo Bioworks Announces Acquisition Of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC; Terms Not Disclosed

Acquisition to enable Ginkgo to bolster its growing biosecurity platform and provide expanded COVID-19 testing options to communities in Massachusetts and beyond

People

Dipanjan BanchurSince

722 stories

de Bruin

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Ark Investment Management

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.